Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Holly Ingraham, PH.D, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentCMP (Cellular Molecular Pha)
    Address1550 4th Street, Bldg 19B
    San Francisco CA 94158
    Phone415-476-2731

       ORNG Applications 
       Websites
       NIH Awarded Grants
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Blind RD, Sablin EP, Kuchenbecker KM, Chiu HJ, Deacon AM, Das D, Fletterick RJ, Ingraham HA. The signaling phospholipid PIP3 creates a new interaction surface on the nuclear receptor SF-1. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15054-9.
        View in: PubMed
      2. Cheung CC, Kurrasch DM, Liang JK, Ingraham HA. Genetic labeling of steroidogenic factor-1 (SF-1) neurons in mice reveals ventromedial nucleus of the hypothalamus (VMH) circuitry beginning at neurogenesis and development of a separate non-SF-1 neuronal cluster in the ventrolateral VMH. J Comp Neurol. 2013 Apr 15; 521(6):1268-88.
        View in: PubMed
      3. Blind RD, Suzawa M, Ingraham HA. Direct modification and activation of a nuclear receptor-PIP2 complex by the inositol lipid kinase IPMK. Sci Signal. 2012 Jun 19; 5(229):ra44.
        View in: PubMed
      4. Ziv L, Muto A, Schoonheim PJ, Meijsing SH, Strasser D, Ingraham HA, Schaaf MJ, Yamamoto KR, Baier H. An affective disorder in zebrafish with mutation of the glucocorticoid receptor. Mol Psychiatry. 2013 Jun; 18(6):681-91.
        View in: PubMed
      5. Lee FY, Faivre EJ, Suzawa M, Lontok E, Ebert D, Cai F, Belsham DD, Ingraham HA. Eliminating SF-1 (NR5A1) sumoylation in vivo results in ectopic hedgehog signaling and disruption of endocrine development. Dev Cell. 2011 Aug 16; 21(2):315-27.
        View in: PubMed
      6. Ingraham HA. Metabolism: A lipid for fat disorders. Nature. 2011 Jun 23; 474(7352):455-6.
        View in: PubMed
      7. Hayes TB, Anderson LL, Beasley VR, de Solla SR, Iguchi T, Ingraham H, Kestemont P, Kniewald J, Kniewald Z, Langlois VS, Luque EH, McCoy KA, Muñoz-de-Toro M, Oka T, Oliveira CA, Orton F, Ruby S, Suzawa M, Tavera-Mendoza LE, Trudeau VL, Victor-Costa AB, Willingham E. Demasculinization and feminization of male gonads by atrazine: consistent effects across vertebrate classes. J Steroid Biochem Mol Biol. 2011 Oct; 127(1-2):64-73.
        View in: PubMed
      8. Whitby RJ, Stec J, Blind RD, Dixon S, Leesnitzer LM, Orband-Miller LA, Williams SP, Willson TM, Xu R, Zuercher WJ, Cai F, Ingraham HA. Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2). J Med Chem. 2011 Apr 14; 54(7):2266-81.
        View in: PubMed
      9. Blackshaw S, Scholpp S, Placzek M, Ingraham H, Simerly R, Shimogori T. Molecular pathways controlling development of thalamus and hypothalamus: from neural specification to circuit formation. J Neurosci. 2010 Nov 10; 30(45):14925-30.
        View in: PubMed
      10. Mullaney BC, Blind RD, Lemieux GA, Perez CL, Elle IC, Faergeman NJ, Van Gilst MR, Ingraham HA, Ashrafi K. Regulation of C. elegans fat uptake and storage by acyl-CoA synthase-3 is dependent on NR5A family nuclear hormone receptor nhr-25. Cell Metab. 2010 Oct 6; 12(4):398-410.
        View in: PubMed
      11. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res. 2009 Jul 1; 69(13):5415-23.
        View in: PubMed
      12. Kurrasch DM, Nevin LM, Wong JS, Baier H, Ingraham HA. Neuroendocrine transcriptional programs adapt dynamically to the supply and demand for neuropeptides as revealed in NSF mutant zebrafish. Neural Dev. 2009; 4:22.
        View in: PubMed
      13. Sablin EP, Woods A, Krylova IN, Hwang P, Ingraham HA, Fletterick RJ. The structure of corepressor Dax-1 bound to its target nuclear receptor LRH-1. Proc Natl Acad Sci U S A. 2008 Nov 25; 105(47):18390-5.
        View in: PubMed
      14. Sablin EP, Blind RD, Krylova IN, Ingraham JG, Cai F, Williams JD, Fletterick RJ, Ingraham HA. Structure of SF-1 bound by different phospholipids: evidence for regulatory ligands. Mol Endocrinol. 2009 Jan; 23(1):25-34.
        View in: PubMed
      15. Campbell LA, Faivre EJ, Show MD, Ingraham JG, Flinders J, Gross JD, Ingraham HA. Decreased recognition of SUMO-sensitive target genes following modification of SF-1 (NR5A1). Mol Cell Biol. 2008 Dec; 28(24):7476-86.
        View in: PubMed
      16. Suzawa M, Ingraham HA. The herbicide atrazine activates endocrine gene networks via non-steroidal NR5A nuclear receptors in fish and mammalian cells. PLoS One. 2008; 3(5):e2117.
        View in: PubMed
      17. Kurrasch DM, Cheung CC, Lee FY, Tran PV, Hata K, Ingraham HA. The neonatal ventromedial hypothalamus transcriptome reveals novel markers with spatially distinct patterning. J Neurosci. 2007 Dec 12; 27(50):13624-34.
        View in: PubMed
      18. Benoit G, Cooney A, Giguere V, Ingraham H, Lazar M, Muscat G, Perlmann T, Renaud JP, Schwabe J, Sladek F, Tsai MJ, Laudet V. International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev. 2006 Dec; 58(4):798-836.
        View in: PubMed
      19. Tran PV, Akana SF, Malkovska I, Dallman MF, Parada LF, Ingraham HA. Diminished hypothalamic bdnf expression and impaired VMH function are associated with reduced SF-1 gene dosage. J Comp Neurol. 2006 Oct 10; 498(5):637-48.
        View in: PubMed
      20. Ingraham HA, Redinbo MR. Orphan nuclear receptors adopted by crystallography. Curr Opin Struct Biol. 2005 Dec; 15(6):708-15.
        View in: PubMed
      21. Lee MB, Lebedeva LA, Suzawa M, Wadekar SA, Desclozeaux M, Ingraham HA. The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. Mol Cell Biol. 2005 Mar; 25(5):1879-90.
        View in: PubMed
      22. Krylova IN, Sablin EP, Moore J, Xu RX, Waitt GM, MacKay JA, Juzumiene D, Bynum JM, Madauss K, Montana V, Lebedeva L, Suzawa M, Williams JD, Williams SP, Guy RK, Thornton JW, Fletterick RJ, Willson TM, Ingraham HA. Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell. 2005 Feb 11; 120(3):343-55.
        View in: PubMed
      23. Bland ML, Fowkes RC, Ingraham HA. Differential requirement for steroidogenic factor-1 gene dosage in adrenal development versus endocrine function. Mol Endocrinol. 2004 Apr; 18(4):941-52.
        View in: PubMed
      24. Jordan BK, Shen JH, Olaso R, Ingraham HA, Vilain E. Wnt4 overexpression disrupts normal testicular vasculature and inhibits testosterone synthesis by repressing steroidogenic factor 1/beta-catenin synergy. Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10866-71.
        View in: PubMed
      25. Fowkes RC, Desclozeaux M, Patel MV, Aylwin SJ, King P, Ingraham HA, Burrin JM. Steroidogenic factor-1 and the gonadotrope-specific element enhance basal and pituitary adenylate cyclase-activating polypeptide-stimulated transcription of the human glycoprotein hormone alpha-subunit gene in gonadotropes. Mol Endocrinol. 2003 Nov; 17(11):2177-88.
        View in: PubMed
      26. Sablin EP, Krylova IN, Fletterick RJ, Ingraham HA. Structural basis for ligand-independent activation of the orphan nuclear receptor LRH-1. Mol Cell. 2003 Jun; 11(6):1575-85.
        View in: PubMed
      27. Bland ML, Desclozeaux M, Ingraham HA. Tissue growth and remodeling of the embryonic and adult adrenal gland. Ann N Y Acad Sci. 2003 May; 995:59-72.
        View in: PubMed
      28. Tran PV, Lee MB, Marín O, Xu B, Jones KR, Reichardt LF, Rubenstein JR, Ingraham HA. Requirement of the orphan nuclear receptor SF-1 in terminal differentiation of ventromedial hypothalamic neurons. Mol Cell Neurosci. 2003 Apr; 22(4):441-53.
        View in: PubMed
      29. Huber BR, Desclozeaux M, West BL, Cunha-Lima ST, Nguyen HT, Baxter JD, Ingraham HA, Fletterick RJ. Thyroid hormone receptor-beta mutations conferring hormone resistance and reduced corepressor release exhibit decreased stability in the N-terminal ligand-binding domain. Mol Endocrinol. 2003 Jan; 17(1):107-16.
        View in: PubMed
      30. Desclozeaux M, Krylova IN, Horn F, Fletterick RJ, Ingraham HA. Phosphorylation and intramolecular stabilization of the ligand binding domain in the nuclear receptor steroidogenic factor 1. Mol Cell Biol. 2002 Oct; 22(20):7193-203.
        View in: PubMed
      31. Roberts LM, Visser JA, Ingraham HA. Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development. Development. 2002 Mar; 129(6):1487-96.
        View in: PubMed
      32. Shen JH, Ingraham HA. Regulation of the orphan nuclear receptor steroidogenic factor 1 by Sox proteins. Mol Endocrinol. 2002 Mar; 16(3):529-40.
        View in: PubMed
      33. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, Uilenbroek JT, Grootegoed JA, Themmen AP. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002 Mar; 143(3):1076-84.
        View in: PubMed
      34. Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingraham HA. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling. Mol Endocrinol. 2001 Jun; 15(6):936-45.
        View in: PubMed
      35. McGee EA, Smith R, Spears N, Nachtigal MW, Ingraham H, Hsueh AJ. Müllerian inhibitory substance induces growth of rat preantral ovarian follicles. Biol Reprod. 2001 Jan; 64(1):293-8.
        View in: PubMed
      36. Bland ML, Jamieson CA, Akana SF, Bornstein SR, Eisenhofer G, Dallman MF, Ingraham HA. Haploinsufficiency of steroidogenic factor-1 in mice disrupts adrenal development leading to an impaired stress response. Proc Natl Acad Sci U S A. 2000 Dec 19; 97(26):14488-93.
        View in: PubMed
      37. Bland ML, Jamieson C, Akana S, Dallman M, Ingraham HA. Gene dosage effects of steroidogenic factor 1 (SF-1) in adrenal development and the stress. Endocr Res. 2000 Nov; 26(4):515-6.
        View in: PubMed
      38. Ingraham HA, Hirokawa Y, Roberts LM, Mellon SH, McGee E, Nachtigal MW, Visser JA. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction. Recent Prog Horm Res. 2000; 55:53-67; discussion 67-8.
        View in: PubMed
      39. Roberts LM, Shen J, Ingraham HA. New solutions to an ancient riddle: defining the differences between Adam and Eve. Am J Hum Genet. 1999 Oct; 65(4):933-42.
        View in: PubMed
      40. Hammer GD, Ingraham HA. Steroidogenic factor-1: its role in endocrine organ development and differentiation. Front Neuroendocrinol. 1999 Jul; 20(3):199-223.
        View in: PubMed
      41. Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL, Ingraham HA. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. Mol Cell. 1999 Apr; 3(4):521-6.
        View in: PubMed
      42. Roberts LM, Hirokawa Y, Nachtigal MW, Ingraham HA. Paracrine-mediated apoptosis in reproductive tract development. Dev Biol. 1999 Apr 1; 208(1):110-22.
        View in: PubMed
      43. Bedford FK, Julius D, Ingraham HA. Neuronal expression of the 5HT3 serotonin receptor gene requires nuclear factor 1 complexes. J Neurosci. 1998 Aug 15; 18(16):6186-94.
        View in: PubMed
      44. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer GD, Ingraham HA. Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell. 1998 May 1; 93(3):445-54.
        View in: PubMed
      45. Giuili G, Shen WH, Ingraham HA. The nuclear receptor SF-1 mediates sexually dimorphic expression of Mullerian Inhibiting Substance, in vivo. Development. 1997 May; 124(9):1799-807.
        View in: PubMed
      46. Nachtigal MW, Ingraham HA. Bioactivation of Müllerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc Natl Acad Sci U S A. 1996 Jul 23; 93(15):7711-6.
        View in: PubMed
      47. Bedford FK, Christopherson K, Nachtigal MW, Shen WH, Julius DJ, Ingraham HA. Molecular biology of pituitary development and disease. Horm Res. 1996; 45 Suppl 1:19-21.
        View in: PubMed
      48. Ingraham HA, Lala DS, Ikeda Y, Luo X, Shen WH, Nachtigal MW, Abbud R, Nilson JH, Parker KL. The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis. Genes Dev. 1994 Oct 1; 8(19):2302-12.
        View in: PubMed
      49. Shen WH, Moore CC, Ikeda Y, Parker KL, Ingraham HA. Nuclear receptor steroidogenic factor 1 regulates the müllerian inhibiting substance gene: a link to the sex determination cascade. Cell. 1994 Jun 3; 77(5):651-61.
        View in: PubMed
      50. Ikeda Y, Shen WH, Ingraham HA, Parker KL. Developmental expression of mouse steroidogenic factor-1, an essential regulator of the steroid hydroxylases. Mol Endocrinol. 1994 May; 8(5):654-62.
        View in: PubMed
      51. Pfäffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, Van der Nat H, Van den Brande JL, Rosenfeld MG, Ingraham HA. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science. 1992 Aug 21; 257(5073):1118-21.
        View in: PubMed
      52. Carpenter CD, Ingraham HA, Cochet C, Walton GM, Lazar CS, Sowadski JM, Rosenfeld MG, Gill GN. Structural analysis of the transmembrane domain of the epidermal growth factor receptor. J Biol Chem. 1991 Mar 25; 266(9):5750-5.
        View in: PubMed
      53. Chen RP, Ingraham HA, Treacy MN, Albert VR, Wilson L, Rosenfeld MG. Autoregulation of pit-1 gene expression mediated by two cis-active promoter elements. Nature. 1990 Aug 9; 346(6284):583-6.
        View in: PubMed
      54. Heisermann GJ, Wiley HS, Walsh BJ, Ingraham HA, Fiol CJ, Gill GN. Mutational removal of the Thr669 and Ser671 phosphorylation sites alters substrate specificity and ligand-induced internalization of the epidermal growth factor receptor. J Biol Chem. 1990 Aug 5; 265(22):12820-7.
        View in: PubMed
      55. Ingraham HA, Flynn SE, Voss JW, Albert VR, Kapiloff MS, Wilson L, Rosenfeld MG. The POU-specific domain of Pit-1 is essential for sequence-specific, high affinity DNA binding and DNA-dependent Pit-1-Pit-1 interactions. Cell. 1990 Jun 15; 61(6):1021-33.
        View in: PubMed
      56. Simmons DM, Voss JW, Ingraham HA, Holloway JM, Broide RS, Rosenfeld MG, Swanson LW. Pituitary cell phenotypes involve cell-specific Pit-1 mRNA translation and synergistic interactions with other classes of transcription factors. Genes Dev. 1990 May; 4(5):695-711.
        View in: PubMed
      57. Ingraham HA, Albert VR, Chen RP, Crenshaw 3d EB, Elsholtz HP, He X, Kapiloff MS, Mangalam HJ, Swanson LW, Treacy MN, et al. A family of POU-domain and Pit-1 tissue-specific transcription factors in pituitary and neuroendocrine development. Annu Rev Physiol. 1990; 52:773-91.
        View in: PubMed
      58. He X, Treacy MN, Simmons DM, Ingraham HA, Swanson LW, Rosenfeld MG. Expression of a large family of POU-domain regulatory genes in mammalian brain development. Nature. 1989 Jul 6; 340(6228):35-41.
        View in: PubMed
      59. Mangalam HJ, Albert VR, Ingraham HA, Kapiloff M, Wilson L, Nelson C, Elsholtz H, Rosenfeld MG. A pituitary POU domain protein, Pit-1, activates both growth hormone and prolactin promoters transcriptionally. Genes Dev. 1989 Jul; 3(7):946-58.
        View in: PubMed
      60. Herr W, Sturm RA, Clerc RG, Corcoran LM, Baltimore D, Sharp PA, Ingraham HA, Rosenfeld MG, Finney M, Ruvkun G, et al. The POU domain: a large conserved region in the mammalian pit-1, oct-1, oct-2, and Caenorhabditis elegans unc-86 gene products. Genes Dev. 1988 Dec; 2(12A):1513-6.
        View in: PubMed
      61. Ingraham HA, Chen RP, Mangalam HJ, Elsholtz HP, Flynn SE, Lin CR, Simmons DM, Swanson L, Rosenfeld MG. A tissue-specific transcription factor containing a homeodomain specifies a pituitary phenotype. Cell. 1988 Nov 4; 55(3):519-29.
        View in: PubMed
      62. Gill GN, Chen WS, Lazar CS, Glenney JR, Wiley HS, Ingraham HA, Rosenfeld MG. Role of intrinsic protein tyrosine kinase in function and metabolism of the epidermal growth factor receptor. Cold Spring Harb Symp Quant Biol. 1988; 53 Pt 1:467-76.
        View in: PubMed
      63. Ingraham HA, Evans GA. Characterization of two atypical promoters and alternate mRNA processing in the mouse Thy-1.2 glycoprotein gene. Mol Cell Biol. 1986 Aug; 6(8):2923-31.
        View in: PubMed
      64. Ingraham HA, Dickey L, Goulian M. DNA fragmentation and cytotoxicity from increased cellular deoxyuridylate. Biochemistry. 1986 Jun 3; 25(11):3225-30.
        View in: PubMed
      65. Ingraham HA, Lawless GM, Evans GA. The mouse Thy-1.2 glycoprotein gene: complete sequence and identification of an unusual promoter. J Immunol. 1986 Feb 15; 136(4):1482-9.
        View in: PubMed
      66. Goulian M, Bleile BM, Dickey LM, Grafstrom RH, Ingraham HA, Neynaber SA, Peterson MS, Tseng BY. Mechanism of thymineless death. Adv Exp Med Biol. 1986; 195 Pt B:89-95.
        View in: PubMed
      67. Evans GA, Ingraham HA, Lewis K, Cunningham K, Seki T, Moriuchi T, Chang HC, Silver J, Hyman R. Expression of the Thy-1 glycoprotein gene by DNA-mediated gene transfer. Proc Natl Acad Sci U S A. 1984 Sep; 81(17):5532-6.
        View in: PubMed
      68. Peterson MS, Ingraham HA, Goulian M. 2'-deoxyribosyl analogues of UDP-N-acetylglucosamine in cells treated with methotrexate or 5-fluorodeoxyuridine. J Biol Chem. 1983 Sep 25; 258(18):10831-4.
        View in: PubMed
      69. Patrick J, Ballivet M, Boas L, Claudio T, Forrest J, Ingraham H, Mason P, Stengelin S, Ueno S, Heinemann S. Molecular cloning of the acetylcholine receptor. Cold Spring Harb Symp Quant Biol. 1983; 48 Pt 1:71-8.
        View in: PubMed
      70. Ingraham HA, Goulian M. Deoxyuridine triphosphatase: a potential site of interaction with pyrimidine nucleotide analogues. Biochem Biophys Res Commun. 1982 Dec 15; 109(3):746-52.
        View in: PubMed
      71. Ingraham HA, Tseng BY, Goulian M. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharmacol. 1982 Jan; 21(1):211-6.
        View in: PubMed
      72. Ingraham HA, Tseng BY, Goulian M. Mechanism for exclusion of 5-fluorouracil from DNA. Cancer Res. 1980 Apr; 40(4):998-1001.
        View in: PubMed
      73. Ingraham HA, Alhadeff JA. Characterization of sialytransferase in noncancerous and neoplastic human liver tissue. J Natl Cancer Inst. 1978 Dec; 61(6):1371-4.
        View in: PubMed
      74. Barrieux A, Ingraham HA, Nystul S, Rosenfeld MG. Characterization of the association of specific proteins with messenger ribonucleic acid. Biochemistry. 1976 Aug 10; 15(16):3523-8.
        View in: PubMed
      75. Barrieux A, Ingraham HA, David DN, Rosenfeld MG. Isolation of messenger-like ribonucleoproteins. Biochemistry. 1975 May 6; 14(9):1815-21.
        View in: PubMed
      76. INGRAHAM HA, GARDNER MM, HEUS EG. A report on 159 third degree lacerations. Am J Obstet Gynecol. 1949 Apr; 57(4):730-5.
        View in: PubMed
      Holly's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP